A Phase 1 interventional study of ASP1517 in Healthy Subjects, sponsored by Astellas Pharma Inc. Completed at 1 site in Japan. Open to male participants aged 20 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-24.
Sponsored by Astellas Pharma Inc · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to evaluate the effect of food on the pharmacokinetics of a single oral dose of ASP1517 in non-elderly healthy adult male subjects.
Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive a single oral dose of ASP1517 under fasting conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fed conditions in period 2.
Drug: ASP1517
Subjects will receive a single oral dose of ASP1517 under fed conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fasting conditions in period 2.
Drug: ASP1517
Oral
Pharmacokinetics (PK) parameter of ASP1517 in Plasma: AUCinf
AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity
Time frame: Up to Day 4 of each treatment period
PK parameter of ASP1517 in Plasma: Cmax
Cmax: Maximum concentration
Time frame: Up to Day 4 of each treatment period
PK parameter of ASP1517 in Plasma: AUClast
AUClast: Area under the concentration-time curve from the time of dosing to the last measurable concentration
Time frame: Up to Day 4 of each treatment period
PK parameter of ASP1517 in Plasma: CL/F
CL/F: Apparent total systemic clearance
Time frame: Up to Day 4 of each treatment period
PK parameter of ASP1517 in Plasma: λz
λz: Terminal rate constant
Time frame: Up to Day 4 of each treatment period
PK parameter of ASP1517 in Plasma: MRTinf
MRTinf: Mean residence time extrapolated to infinity
Time frame: Up to Day 4 of each treatment period
PK parameter of ASP1517 in Plasma: t1/2
t1/2: Terminal elimination half-life
Time frame: Up to Day 4 of each treatment period
PK parameter of ASP1517 in Plasma: tmax
tmax: Time of Cmax
Time frame: Up to Day 4 of each treatment period
PK parameter of ASP1517 in Plasma: tlag
tlag: Lag time
Time frame: Up to Day 4 of each treatment period
PK parameter of ASP1517 in Plasma: Vz/F
Vz/F: Apparent volume of distribution during the terminal elimination phase
Time frame: Up to Day 4 of each treatment period
PK parameter of ASP1517 in Urine: Ae
Ae: Cumulative amount of ASP1517 excreted into urine
Time frame: Up to Day 4 of each treatment period
PK parameter of ASP1517 in Urine: CLR
CLR: Renal clearance
Time frame: Up to Day 4 of each treatment period
Safety assessed by adverse events
Time frame: Up to Day 9 of Period 2
Number of participants with abnormal vital signs and/or adverse events during treatment period
Time frame: Up to Day 9 of Period 2
Number of participants with abnormal laboratory values and/or adverse events during treatment period
Time frame: Up to Day 9 of Period 2
Number of participants with abnormal standard 12-Lead ECG and/or adverse events during treatment period
ECG: Electrocardiogram
Time frame: Up to Day 9 of Period 2
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Jul 2016, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roxadustat